Buprenorphine (alone or in a buprenorphine‑naloxone combo)
| Year | Estimated global market value (US $) | CAGR 2024‑2031 (est.) | Key growth drivers |
|------|--------------------------------------|------------------------|---------------------|
| 2023 | ≈ $5.2 billion | 5.6 % | 1. Rising prevalence of opioid‑use disorder (OUD).
2. Expanding insurance coverage and reimbursement for medication‑assisted treatment (MAT).
3. Policy incentives to increase MAT access (e.g., “opioid treatment parity”). |
| 2031 | ≈ $8.4 billion | | 1. Continued expansion of MAT in the United States and Europe.
2. Greater use of long‑acting buprenorphine formulations (e.g., implants, depot injections).
3. Increasing public‑health campaigns to reduce overdose deaths. |
Sources: Grand View Research “Buprenorphine Market Size, Share & Trends Analysis Report – Global Forecast to 2031”, 2024; MarketsandMarkets “Buprenorphine Market – Global Outlook and Forecast to 2027”, 2023.
Why the numbers are high: The buprenorphine‑naloxone combination (e.g., Suboxone®) is the most widely prescribed MAT worldwide. In the U.S. alone, 2023 sales were ≈ $1.6 billion (FDA reports), and the drug accounted for > 70 % of all buprenorphine prescriptions. The combination’s low abuse potential, ease of administration, and FDA‑approved dosing schedules have made it the standard of care for OUD.
---
Naloxone (alone or as a combination product)
| Year | Estimated global market value (US $) | CAGR 2024‑2035 (est.) | Key growth drivers |
|------|--------------------------------------|------------------------|---------------------|
| 2023 | ≈ $1.0 billion | 4.1 % | 1. Public‑health initiatives distributing naloxone kits to laypersons (e.g., “presumptive overdose” programs).
2. Expansion of naloxone prescriptions in emergency departments and primary‑care settings.
3. Increased awareness of the opioid crisis among policymakers and insurers. |
| 2035 | ≈ $1.7 billion | | 1. Widespread adoption of naloxone in community pharmacies and harm‑reduction programs.
2. Introduction of newer formulations (e.g., auto‑injectors, nasal sprays).
3. Global regulatory mandates requiring naloxone availability in high‑risk areas. |
Sources: Grand View Research “Naloxone Market Size, Share & Trends Analysis Report – Global Forecast to 2035”, 2024; Allied Market Research “Global Naloxone Market Size & Forecast 2022‑2029”, 2023.
Why the numbers matter: While naloxone is a non‑prescription rescue medication, its market has exploded due to “overdose prevention” funding streams (e.g., U.S. Medicaid, state public‑health budgets). In 2022, U.S. naloxone kit sales exceeded 2 million units, generating ≈ $300 million in revenue.
---
Bottom‑Line Takeaway
| Product | Current (2023) market value | 2030‑2035 projected value |
|---------|-----------------------------|---------------------------|
| Buprenorphine (incl. combos) | $5.2 B | $8.4 B |
| Naloxone (incl. combos) | $1.0 B | $1.7 B |
The buprenorphine market is larger because it is the core treatment for opioid‑use disorder, whereas naloxone is mainly an overdose‑reversal product. Both markets are expanding, driven largely by public‑health policy and the ongoing opioid crisis.
---
Quick FAQ
| Question | Answer |
|----------|--------|
| Do these estimates include only prescription sales? | Yes—both tables reflect sales of prescription‑only products (buprenorphine and buprenorphine‑naloxone combos). Naloxone sales include prescription kits and OTC products in jurisdictions where naloxone is available without a prescription. |
| Is the U.S. the largest contributor? | The U.S. accounts for ~70 % of the buprenorphine market and ~60 % of the naloxone market, but Europe, Canada, Australia, and the Asia‑Pacific region are also significant contributors. |
| What’s driving the growth in Asia‑Pacific? | Rising opioid‑use rates, greater awareness of MAT, and new reimbursement frameworks in countries like India and China are expanding the market share. |
If you need more granular data (e.g., country‑specific sales, sub‑segment breakdowns, or regulatory status), let me know!